guest ::
| Home > Publications database > Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model > print |
| Home > Publications database > Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model > print |
| 001 | 9878 | ||
| 005 | 20200402210429.0 | ||
| 024 | 7 | _ | |2 pmid |a pmid:19954305 |
| 024 | 7 | _ | |2 DOI |a 10.1089/rej.2009.0926 |
| 024 | 7 | _ | |2 WOS |a WOS:000277602200019 |
| 024 | 7 | _ | |a altmetric:21804053 |2 altmetric |
| 037 | _ | _ | |a PreJuSER-9878 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 084 | _ | _ | |2 WoS |a Geriatrics & Gerontology |
| 100 | 1 | _ | |a Liu, H. |b 0 |u FZJ |0 P:(DE-Juel1)VDB4104 |
| 245 | _ | _ | |a Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model |
| 260 | _ | _ | |a Larchmont, NY |b Liebert |c 2010 |
| 300 | _ | _ | |a |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 440 | _ | 0 | |a Rejuvenation Research |x 1549-1684 |0 18202 |y 2 |v 13 |
| 500 | _ | _ | |a Record converted from VDB: 12.11.2012 |
| 520 | _ | _ | |a Previously, two D-enantiomeric amino acid peptides, D1 and D3, which specifically bind to the amyloid-beta peptide Abeta(1-42), were identified by phage display selection. To assess the diagnostic and therapeutic potentials of D1 and D3 for the diagnosis and treatment of Alzheimer disease, the blood-brain barrier transport of these D-peptides was quantitatively evaluated in vitro. Our results showed that the apical-to-basolateral transport of D3 was more efficient than that of D1. An active efflux transport mechanism seems to oppose the transport of D1, whereas D3 is likely to be transported through the blood-brain barrier via an adsorptive-mediated transcytosis mechanism. |
| 536 | _ | _ | |a Funktion und Dysfunktion des Nervensystems |c P33 |2 G:(DE-HGF) |0 G:(DE-Juel1)FUEK409 |x 0 |
| 536 | _ | _ | |a BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |c P45 |0 G:(DE-Juel1)FUEK505 |x 1 |
| 588 | _ | _ | |a Dataset connected to Web of Science, Pubmed |
| 650 | _ | 2 | |2 MeSH |a Alzheimer Disease: metabolism |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: chemistry |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: metabolism |
| 650 | _ | 2 | |2 MeSH |a Animals |
| 650 | _ | 2 | |2 MeSH |a Blood-Brain Barrier: metabolism |
| 650 | _ | 2 | |2 MeSH |a Cells, Cultured |
| 650 | _ | 2 | |2 MeSH |a Dose-Response Relationship, Drug |
| 650 | _ | 2 | |2 MeSH |a Models, Theoretical |
| 650 | _ | 2 | |2 MeSH |a Oligopeptides: metabolism |
| 650 | _ | 2 | |2 MeSH |a Oligopeptides: pharmacokinetics |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: metabolism |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: pharmacokinetics |
| 650 | _ | 2 | |2 MeSH |a Protein Binding |
| 650 | _ | 2 | |2 MeSH |a Protein Transport |
| 650 | _ | 2 | |2 MeSH |a Rats |
| 650 | _ | 2 | |2 MeSH |a Validation Studies as Topic |
| 650 | _ | 2 | |2 MeSH |a Verapamil: pharmacokinetics |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Amyloid beta-Peptides |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a D1 peptide |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a D3 peptide |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Oligopeptides |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Peptide Fragments |
| 650 | _ | 7 | |0 52-53-9 |2 NLM Chemicals |a Verapamil |
| 650 | _ | 7 | |a J |2 WoSType |
| 700 | 1 | _ | |a Funke, S. A. |b 1 |u FZJ |0 P:(DE-Juel1)VDB65869 |
| 700 | 1 | _ | |a Willbold, D. |b 2 |u FZJ |0 P:(DE-Juel1)132029 |
| 773 | _ | _ | |a 10.1089/rej.2009.0926 |g Vol. 13 |q 13 |0 PERI:(DE-600)2155984-3 |t Rejuvenation research |v 13 |y 2010 |x 1549-1684 |
| 909 | C | O | |o oai:juser.fz-juelich.de:9878 |p VDB |
| 913 | 1 | _ | |k P33 |v Funktion und Dysfunktion des Nervensystems |l Funktion und Dysfunktion des Nervensystems |b Gesundheit |0 G:(DE-Juel1)FUEK409 |x 0 |
| 913 | 1 | _ | |k P45 |v BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |l Biologische Informationsverarbeitung |b Schlüsseltechnologien |0 G:(DE-Juel1)FUEK505 |x 1 |
| 914 | 1 | _ | |y 2010 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed |
| 920 | 1 | _ | |d 31.12.2010 |g ISB |k ISB-3 |l Strukturbiochemie |0 I:(DE-Juel1)VDB942 |x 0 |
| 920 | 1 | _ | |0 I:(DE-82)080012_20140620 |k JARA-HPC |l Jülich Aachen Research Alliance - High-Performance Computing |g JARA |x 1 |
| 970 | _ | _ | |a VDB:(DE-Juel1)119985 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a I:(DE-82)080012_20140620 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 981 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 981 | _ | _ | |a I:(DE-Juel1)VDB1346 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|